ArticleFrontiers in immunology2025

Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study.

Shida Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.